Tech Company Financing Transactions
Enlaza Therapeutics Funding Round
On 12/19/2022, Enlaza Therapeutics landed $61 million in Seed funding from Avalon Ventures, Frazier Life Sciences and Lightspeed Venture Partners.
Transaction Overview
Company Name
Announced On
12/19/2022
Transaction Type
Venture Equity
Amount
$61,000,000
Round
Seed
Investors
Proceeds Purpose
The company intends to use the funds to advance its proprietary War-Lock platform and build a pipeline of covalent biologics with an initial focus on developing novel, differentiated cancer therapeutics with targeted efficacy and low toxicity.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
11099 North Torrey Pines Rd 280
La Jolla, CA 92037
USA
La Jolla, CA 92037
USA
Phone
Undisclosed
Website
Email Address
Overview
Enlaza is creating a groundbreaking new class of protein therapeutics that deliver more efficacious and safer treatments for patients. Enlaza's breakthrough War-LockTM technology enables generation of unique, highly-selective biologic drugs that are engineered to become warheads with the capacity to irreversibly lock to disease related targets. We leverage our novel synthetic biology platform, coupled with proprietary amino acids, to precision-engineer biological medicines with improved efficacy and safety profiles.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 12/19/2022: Husslup venture capital transaction
Next: 12/19/2022: Pocketnest venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to document funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs